Three New Drugs, Thirty Years of Resistance to Work Around
Three genuinely novel agents, each active by a different mechanism than the resistance sitting in his chart, and no head-to-head trial to settle which combination actually fits a patient whose treatment history predates all three of them.
F.D., a 61-year-old man, was diagnosed with HIV in 1991, three years before the first protease inhibitor reached the market, and has outlived two of the friends who were diagnosed alongside him that same year — a fact he mentions plainly, without drama, the way someone describes a piece of their own history. He spent his working years as a graphic designer and now volunteers running a peer-support group for other long-term survivors, work he says gives structure to weeks that used to be organized entirely around clinic visits and pill counts. Over three decades he has cycled through nearly every antiretroviral class as each new option arrived, with several periods of viral rebound along the way — some from genuine drug toxicity, some from the harder years of the epidemic when adherence support looked nothing like it does now. His chart runs to several volumes at this point, and his current care team is the fourth he's had since 1991, the first three having closed, merged, or simply lost the clinicians he'd originally seen.
His most recent genotype and phenotype, drawn six weeks ago, show resistance affecting all four original antiretroviral classes — NRTIs, NNRTIs, protease inhibitors, and integrase inhibitors — with only partial residual activity from any single remaining option in each. His CD4 count is 140 cells/µL and his viral load is 42,000 copies/mL, not a crisis but not controlled. Three genuinely novel agents, each active through a mechanism outside his existing resistance, are now real options for building an optimized background regimen: ibalizumab, a CD4-directed monoclonal antibody that TMB-301 showed producing real virologic response in a population much like his; fostemsavir, an oral gp120-attachment inhibitor BRIGHTE tested in a comparably treatment-experienced cohort; and lenacapavir, a capsid-assembly inhibitor CAPELLA studied in a similarly resistant population. No trial has compared the three directly against each other in a salvage combination, and his own three decades of sequential regimen changes mean whichever option the team chooses is being added to a treatment history longer than any of the three drugs themselves have existed.
HIV specialty clinic, salvage-regimen planning visit
His resistance spans all four original classes, so the most direct answer is a drug whose activity doesn't depend on any of them. Ibalizumab binds domain 2 of the CD4 receptor itself, not a viral target — TMB-301 showed a real virologic-response rate in a population with baseline resistance much like his. I'd build the regimen around it.
Mechanism-independence is real and I'm not disputing the trial result.
But ibalizumab requires an infusion visit every two weeks, indefinitely — there's no step-down to monthly; the label is a 2,000mg load and then 800mg every fourteen days for as long as he stays on it. He's spent thirty years organizing his life around exactly that kind of recurring clinic burden. I'll grant that he has reliable transportation and no venous access difficulty, so the visits themselves are logistically feasible for him specifically in a way they wouldn't be for every patient — but feasible isn't the same as sustainable over years, and 'we could make him do it' shouldn't be the bar. Fostemsavir showed a comparable functional-response rate in BRIGHTE's own heavily treatment-experienced cohort, and it's an oral tablet. For a decades-long survivor, quality of life and long-term sustainability of the regimen are as much a part of 'response' as the virologic number is.
There's a third option that answers the pharmacist's concern even further. Lenacapavir targets capsid assembly, a mechanism distinct from both of the others, and CAPELLA studied it in a comparably resistant population with a comparable response. After an oral lead-in, it's dosed by injection twice a year — the lowest visit burden of the three by a wide margin. My real caveat: it's the newest of the three agents, so it carries the least real-world experience, which is worth naming honestly rather than treating the injection-frequency advantage as costless.
Agreed on lenacapavir plus an individualized optimized background regimen as the starting plan, with both ibalizumab and fostemsavir explicitly recorded as real fallback options rather than ruled out — not a close call the specialist and pharmacist conceded lightly, since all three have genuine trial support in populations resembling his. Not settled: how much weight lenacapavir's limited real-world experience should carry against its convenience advantage, which the primary care physician raised and which the group agreed to revisit at his first follow-up viral load rather than resolve today.